Physician profile
Richard T Allen
NPI 1962660175
$471,394.62
in general payments reported to CMS, 2019-2025
27 companies · $70K in 2025
The $70K reported for 2025 was more than what 90% of Orthopaedic Surgery of The Spine providers received nationally (typical 2025 total: $2,116).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $57K · 2020: $56K · 2021: $33K · 2022: $136K · 2023: $72K · 2024: $47K · 2025: $70K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $156K · Travel and Lodging: $16K · Food and Beverage: $10K · Acquisitions: $7,343 · Gift: $38.35 · Entertainment: $30.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $156,044.79 |
| Travel and Lodging | $15,948.31 |
| Food and Beverage | $10,164.86 |
| Acquisitions | $7,342.95 |
| Gift | $38.35 |
| Entertainment | $30.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $194,493.89 | 2019-2024 | Symphony, Viper, Conduit |
| Depuy Synthes Products, INC. | $112,411.13 | 2019-2024 | Fibulink |
| Kuros Biosciences Ag | $78,583.26 | 2020-2025 | Magnetos |
| Globus Medical, INC. | $47,846.16 | 2019-2025 | Alif, Xlif, Tlif |
| Depuy Synthes Sales INC. | $20,934.70 | 2019-2025 | Acf, Velys |
| Kuros Biosciences USA, INC | $7,788.65 | 2019-2025 | Magnetos |
| Si-Bone, INC. | $5,837.98 | 2019-2025 | |
| Nuvasive, INC. | $991.01 | 2019-2021 | |
| Orthofix Medical, INC. | $569.08 | 2020-2025 | Meridian, Vu A-Pod Prime Nanometalene, Shoreline Rt |
| Alphatec Spine, INC | $389.65 | 2024 | Biologics |
| Seaspine Orthopedics Corporation | $375.89 | 2022 | |
| Medtronic, INC. | $310.48 | 2022-2025 | Atlantis Anterior Cervical Plate System, Navlock, Intellis Adaptivestim |
| Spinal Simplicity, LLC | $196.66 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $139.48 | 2025 | Iovera |
| Surgalign Spine Technologies, INC. | $134.62 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mml US, INC. | $102.50 | 2023 | Reactiv8 |
| Prosidyan, INC | $85.96 | 2019 | |
| Theradaptive, INC. | $38.35 | 2025 | Osteoadapt |
| Djo, LLC | $33.58 | 2022-2023 | Cmf |
| Solventum Corporation | $23.91 | 2025 | Prevena |
| Boston Scientific Corporation | $21.69 | 2020 | |
| Ethicon US, LLC | $21.36 | 2020 | |
| Cerapedics INC. | $19.74 | 2024 | I-Factor Peptide Enhanced Bone Graft |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.16 | 2021 | |
| Zimmer Biomet Holdings, INC. | $14.78 | 2019 | |
| Augmedics INC. | $11.95 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$112,500.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Allen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.